Altimmune, Inc. Stock News

Altimmune is a clinical-stage biopharmaceutical company focused on developing peptide-based treatments for obesity and liver diseases. Their lead drug candidate, Pemvidutide, targets glucagon-like pep

Biotech stocks can offer some of the most explosive, exciting opportunities on the market. That is, if you find the right one.

Altimmune Inc. NASDAQ: ALT is a clinical-stage biotechnology company specializing in treating liver disease and obesity. Their lead drug, Pemvidutide, has garnered much attention as a GLP-1/glucagon d

Right now, biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. All of this is thanks to new innovation, millions of ret

Altimmune (ALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Positive results achieved from phase 2 MOMENTUM study, whereby patients not only achieved significant weight loss over a 48-week period with pemvidutide but also had lean mass preservation. It is said

The results are a sign that Altimmune can address an area of concern around weight loss drugs, which is that they shrink critical muscle mass.

GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 20

Altimmune (NASDAQ: ALT) stock price continued its short squeeze this week, soaring to a high of $14.52, its highest point since February 6th last year. The company's stock surged by more than 580% fro

Altimmune (NASDAQ: ALT ) stock is rising higher on Monday but it's not actually due to any news from the clinical-stage biopharmaceutical company. Instead, a clinical trial update from rival Zealand P

With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explos

Kerrisdale Capital is at it again, this time revealing a short position in struggling biotech firm Altimmune (NASDAQ: ALT ). The acclaimed short seller has just released a damning short report on the

Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.

MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth

Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.